FDA happenings: First “upstream” embolic protection system gains clearance; Cryoablation system deemed approvable with conditions; Shelhigh stops distribution; and more
Reimbursement issues: Medicare members indecisive on paying for renal artery stenting
Around the industry: Kensey Nash terminates its embolic protection line; DES sales continue to decline; Endeavor meets primary endpoint in pivotal trial; and more
Proceedings of TCT 4, 18-20 (2007).
Fluent in Science 